Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing

Jan 20 2017

• By Sten Stovall

Plan B

Related Content

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

Bristol Still Rules Immuno-Oncology, But For How Long?

Oct 27 2016

AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

Jan 18 2017

What's Next For Bristol's Opdivo/Yervoy Combination

Jun 06 2016

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Roche Holding AG

AstraZeneca PLC

Roche Holding AG

Additional Topics

Approvals Business Strategies Commercial Companies ImmunoOncology Cancer BioPharmaceutical

More from Anticancer

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window